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Medical devices are used widely for virtually every disease or condition. Although devices are subject to regulation, the number of recalls, the clinical data requirements for regulation and the impact on patient safety are poorly understood.
Methods
We defined a device using European directives and used publically available information on the MHRA website to determine the number of devices recalled from Jan 2006 to Dec 2010. Two reviewers independently assessed Field Safety Notices and Medical Device Alerts. We wrote to manufacturers to obtain further information and clinical data. We summarized data by year, CE classification, indication, and FDA recall system of severity.
Results
In total 2,124 Field Safety Notices were issued over the 5-year period, an increase of 1,220% (62 in 2006 to 757 in 2010). 447 Medical Device Alerts were issued in the same period and 44% were assessed as a reasonable probability of causing serious adverse health consequences or death. We wrote to 192 manufacturers of withdrawn devices and received 101 (53%) replies, only four (2.1%)
provided the clinical data we requested. Lack of available transparent data prevented full analyses of the safety impact. Of the highest risk recalled devices recalled more than half were related to the cardiovascular system (25%) or musculoskeletal system (33%), and 88% (95% CI, 80% to 97%) were assessed as a reasonable probability of causing serious adverse health consequences or death. For low risk devices the figure was 34% (95%CI, 26% to 42).
Conclusion
The number of medical devices subject to recalls or warnings in the UK has risen dramatically. A substantial number of these devices may have caused serious adverse effects in patients and contributed to health care costs. Significant problems exist in the UK with a lack of access to transparent data and registry of the highest risk devices. • To determine the clinical data required at the time of regulation and the data available at the time of device recall.
Article focus
• To determine the potential risk to patients associated with recalled medical devices.
Key messages
• There was a substantial increase in Field Safety Notices over the 5 year period
• A substantial number of devices may have caused serious adverse effects in patients and contributed to health care costs over this time. But a lack of available transparent clinical data currently prevents full analyses of the safety impact of recalled devices in the UK.
• Of the highest risk devices recalled more than half were related to the cardiovascular system or the musculoskeletal system.
Strengths and limitations of this study

Strengths
• Quantification of all reported device recalls in the UK over a five year period.
• A breakdown by CE marked classification of device.
• An assessment of the potential harms of device recalls based on freely available published data on the MHRA website.
Limitations of this study
• We were limited by a lack of available clinical data of recalled devices and the absence of a central registry, particularly of the highest risk devices, which limited our ability to fully quantify and assess the implications of recalls on patient safety.
• Our classification of devices and FDA recall status was based predominantly on our clinical experience, requiring assumption which means they may differ from manufacturers' classification and other clinicians.
• Owing to a lack of clinical data made available to us, we were unable to determine the reason for the rise in Field Safety Notices. Also we do not know when the problem first arose, and what kind of pre-market clinical testing had been undertaken for many recalled devices. 11 A recent report of 113 recalled devices which caused serious health problems, highlighted most were approved using less stringent processes or were considered so low risk they had been exempt from regulatory review. 12 Approval of US devices takes more time, requiring more clinical data, and many companies now obtain approval in Europe first, often many years before the device appears on the US market. 13 These rates of adverse medical device events and differences in regulatory approval suggest they are an important patient safety issue worldwide, but there has been little evidence from the UK.
Introduction
14 Therefore we aimed to describe the number of medical device recalls in the UK, the clinical data requirements for regulatory approval and determine the subsequent consequences of device recalls for patient safety. 
Methods
For the purposes of this study we defined a medical device using the European medical device directives. These state: a medical device is any instrument, apparatus, appliance, software, material or other article, whether used alone or in combination, including the software intended by its manufacturer, to be used specifically for diagnostic and/or therapeutic purposes and necessary for its proper application, Additionally, the directives state that a medical device does not achieve its principal intended action in or on the human body by pharmacological, immunological or metabolic means, but it may be assisted by such means.
2-4
We used information that is publically available on the MHRA website (www.mhra.gov) to determine the number of devices which had been withdrawn or recalled over the Where disagreement occurred in classification between the two authors this was resolved by discussion.
We also categorized the agreed list of Class 3 devices by their main indication for use either by system (i.e. cardiovascular, gastrointestinal, neurological or orthopaedic), or by mode (diagnostic, surgical instrument, in-vitro device, infusion, imaging, radiotherapy, dialysis, sterilization).
We also planned to determine the potential risk to patients associated with each of the withdrawn devices, using the system of classification employed by the Food and Drug Administration (FDA). The FDA system classifies risk of harm from a device using three levels:
• A situation in which there is a reasonable probability that the use of, or exposure to, a product will cause serious adverse health consequences or death (FDA Class I). • A situation in which use of, or exposure to, a product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote (FDA Class II).
• A situation in which use of, or exposure to, a product is not likely to cause adverse health consequences (FDA Class III).
For Medical Device Alerts we coded whether the device was recalled or withdrawn from the market, and one author (MB) wrote to manufacturers of recalled devices to obtain further information.
Specifically we asked for a copy of all field safety notices issued, the country where the CE marking was registered, the name of the Notifying Body, where the device was manufactured, where the device was packaged and details of clinical data that were submitted or in possession as part of the CE marking process or data that has been published since the product was CE marked (the question are in appendix 1 Therefore, due to insufficient data, we were unable to apply the FDA system of recalls to Field safety Notices. However, the two authors (CH, MT) were able to independently classify the MHRA Medical Device Alerts. 12 Although the Alerts are not exhaustive, they do contain a summary of the problem, the action to be taken and by whom, as well as the distribution list of the alert. Again, disagreements between the two authors were resolved by discussion.
We summarized data by year, by CE classification, by indication, and Medical Device Alerts by FDA recall system, presenting data as raw counts and proportions. Because the FDA recall system was only undertaken on a subset of the data we calculated proportions and associated 95 % confidence intervals and used Cohen's Kappa c as a measure of inter-rater reliability. We analyzed data using Excel and SPSS version 17. to 757 in 2010 (figure 1).
Of the 2,124 Field Safety Notices, 327 (15.4%) were high risk CE Class 3 devices, and more than half were related to the cardiovascular system (25%) or musculoskeletal system (33%). Table 1 shows there were 1,527 (72%) medium risk devices (CE Class 2) and 270 (12.7%) low risk devices (CE Class 1).
Of the 447 Medical Device Alerts, 147 (33%) devices were marked for immediate action and 197 (44%) were to be withdrawn or recalled (Table 2) . We wrote to the manufacturers of 192 withdrawn devices whose contact details were listed on the alerts. We received 101 (53%) replies, of which only four (2.1%) provided the data requested: 21 replies provided partial answers, 11 declined to formally participate, 27 acknowledged the email but provided no response, and 38 emails bounced back due to an incorrect email address or due to an out of office reply. and 31% (23% to 38%) were judged as having a reasonable probability of causing serious adverse health consequences or death respectively. Of the CE Class 1 devices, those which carry the lowest risk, 34% (CI, 26% to 42%) were assessed as a reasonable probability of causing serious adverse health consequences.
Discussion
Main findings
We found a substantial increase in the number of Field Safety Notices issued in the last five years by medical device manufacturers, without concomitant increases in Medical Device Alerts issued by the period, which represents a substantial concern for overall safety and impact on health care costs in the UK.
We were unable to access adequate clinical data or pre-market approval data for recalled devices:
only 2% of manufacturers were forthcoming in providing data. In the very few cases we did receive data these were mainly literature reviews and were not comparable to systematic reviews.
In addition, we found nearly half of Medical Device Alerts were related to devices that had a reasonable probability of causing serious adverse health consequences or death. Moreover, of the most risky devices (CE Class 3 devices) that were recalled nearly 9 out of every 10 were judged independently by two clinicians to have a reasonable probability of causing serious adverse health consequences or death based on the information contained on the MHRA Medical Device Alerts.
However, it was not unusual for us to find low risk devices, CE class I devices, leading to potentially serious adverse events; numerous defective wheelchairs and hoists needed to be recalled which potentially have led to considerable morbidity. it states: 'the central circulatory system now includes the vessels aortic arch and descending aorta to the aortic bifurcation,' whereas in the previous directives it did not. Devices in contact with these vessels will now be considered high risk, whereas, one can only surmise, in the past they were deemed at a lower risk and subject to less stringent data requirements at the regulatory stage.
Implications
Thirdly, are the requirements for pre-approval clinical data fit for purpose in Europe? Pre-approval data for medical devices in Europe does not require demonstration of efficacy. Clinical data used for
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It is particularly concerning we were unable to review any of the clinical data provided to achieve a CE mark, as the relevant data is held by the company or the notifying bodies and not a public body, such as the MHRA. This means they are not subject to the Freedom of Information Act, a means by which researchers can access information. Again this contrasts markedly with the situation for pharmaceuticals, where this information can be obtained, which are regulated by the European Medicines Agency. Surveillance of devices in practice is therefore lax, 17 and whereas we can access mortality data in adult cardiac surgery for named surgeons 18 we cannot currently do the same for named devices in many different specialities and systems.
Finally, how should the current system of regulation be changed? Since device recalls will continue to occur and seem to be increasing, better communication of the risk of the recall should be considered to help clinicians and patients make decisions that allow appropriate risk assessment. 
Limitations
The main limitation of the study was the lack of available data on details of device withdrawals, or quantification of the number or current use of devices affected. Our CE classification of devices and FDA recall status was therefore based predominantly on our clinical experience based on the information that was publically available, and this judgement may therefore differ from manufacturers' classification and form other clinicians. Owing to a lack of data made available to us, we were also unable to determine the reason for the rise in Field Safety Notices, and therefore cannot speculate on when the problem first arose, and more importantly, what kind of clinical testing had been undertaken prior to the device going on the market. The absence of a central registry containing information on how many devices are currently in use in the UK limited our ability to fully assess the implications of our findings on patient safety. This means we are unable to quantify the true number of patient harms caused by medical device recalls Finally, we are unable to determine which of the safety alerts were who needed to be traced, and the workload and costs involved in these actions.
Conclusions
The size and scale of the medical device recalls substantially impacts on NHS workload and patient safety and the number of Field Safety Notices continues to grow. Significant problems exist in the UK with a lack of access to transparent data and registry of the highest risk devices, which prevents a full understanding of the size and impact on patient safety.
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